UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies

JCI insight, 2018-02, Vol.3 (4)

2018

Volltextzugriff (PDF)

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy

Blood advances, 2022-08, Vol.6 (16), p.4859-4872

2022

Volltextzugriff (PDF)

A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy

The Journal of immunology (1950), 2009-08, Vol.183 (4), p.2837-2850

2009

Volltextzugriff (PDF)

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections

Bone marrow transplantation (Basingstoke), 2016-09, Vol.51 (9), p.1163-1172

2016

Volltextzugriff (PDF)

TUMOR FEATURES BEYOND TUMOR SIZE: A POPULATION-LEVEL ANALYSIS OF PATIENTS WITH SURGICALLY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) IN THE SEER MEDICARE DATABASE

Chest, 2022-10, Vol.162 (4), p.A1686-A1687

2022

Volltextzugriff (PDF)

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Blood, 2018-11, Vol.132 (Supplement 1), p.4596-4596

2018

Volltextzugriff (PDF)

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11521-11521

2021

Volltextzugriff (PDF)

Abstract 4978: Adoptively transferred CMV-specific T-cells recognizing dominant and sub-dominant pp65 epitopes demonstrate improved in vivo inhibition of tumor xenografts in combination with PD-1 inhibition

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4978-4978

2017

Volltextzugriff (PDF)

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.3134-3134

2019

Volltextzugriff (PDF)

Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8555-TPS8555

2020

Volltextzugriff (PDF)

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2)

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (15_suppl), p.TPS2661-TPS2661

2021

Volltextzugriff (PDF)

Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies

Discovery medicine, 2009-12, Vol.8 (43), p.210-218

2009

Volltextzugriff (PDF)

Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes

Blood, 2015-12, Vol.126 (23), p.4298-4298

2015

Volltextzugriff (PDF)

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells

Bone marrow transplantation (Basingstoke), 2015-06, Vol.50 Suppl 2 (S2), p.S43-S50

2015

Volltextzugriff (PDF)

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Blood, 2014-12, Vol.124 (21), p.309-309

2014

Volltextzugriff (PDF)

Abstract B050: Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B050-B050

2016

Volltextzugriff (PDF)

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Blood, 2016-12, Vol.128 (22), p.61-61

2016

Volltextzugriff (PDF)

Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors

Blood, 2013-11, Vol.122 (21), p.2021-2021

2013

Volltextzugriff (PDF)

Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Blood, 2017-12, Vol.130 (Suppl_1), p.747-747

2017

Volltextzugriff (PDF)

Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes

Blood, 2012-11, Vol.120 (21), p.1905-1905

2012

Volltextzugriff (PDF)

Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab

Blood, 2005-11, Vol.106 (11), p.1237-1237

2005

Volltextzugriff (PDF)

A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy1

The Journal of immunology (1950), 2009-07, Vol.183 (4), p.2837-2850

2009

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy

A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections

TUMOR FEATURES BEYOND TUMOR SIZE: A POPULATION-LEVEL ANALYSIS OF PATIENTS WITH SURGICALLY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) IN THE SEER MEDICARE DATABASE

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis

Abstract 4978: Adoptively transferred CMV-specific T-cells recognizing dominant and sub-dominant pp65 epitopes demonstrate improved in vivo inhibition of tumor xenografts in combination with PD-1 inhibition

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2)

Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies

Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Abstract B050: Functional characterization of virus specific stem cell like memory T cells, their maturation in vitro, and potential contribution to secondary T cell responses

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors

Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 or CR2 or MDS Including tMDS/AML

Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes

Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS)

Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab

Adoptive Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides of the CMV-pp65 Protein for the Treatment of Persistent CMV Antigenemia Following Allogeneic Hematopoietic Stem Cell Transplants

A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy1

Suchergebnisse filtern